Oct 28, 2023
JS-ON's HIPER, a high-frequency pain therapy device, has successfully launched in Taiwan after obtaining import approval from the Taiwan Food and Drug Administration (TFDA) four years after its initial application.
JS-ON's HIPER, a high-frequency pain therapy device, has successfully launched in Taiwan after obtaining import approval from the Taiwan Food and Drug Administration (TFDA) four years after its initial application. The device was showcased at the Taiwan Medical Device Conference on October 28-29, 2023, as a highlight product of 2023.
The HIPER was met with great interest from hospital officials and medical professionals at the conference. The most frequently asked questions were about the device's safety and efficacy compared to existing high-frequency devices.
Safety:
HIPER is a musculoskeletal pain relief medical device that is differentiated from existing high-frequency devices. JSOn's CRET technology combines the safety of CET technology and the therapeutic effects of RET technology.
In addition, the heat can be transmitted to the body even if the probe coated with a special material does not directly touch the skin, and it can be used without side effects such as tingling or burns.
Efficacy:
As a result of human/animal clinical trials on knee, back, shoulder, and plantar fasciitis with leading hospitals in Korea, a total of 6 clinical papers have been published in international SCIE-level academic journals, "Journal of Clinical Medicine" and "Pain Research and Management."
The clinical paper results clearly proved the efficacy of HIPER.
Those who tried HIPER at the conference said that it was different from existing high-frequency devices in that it did not have tingling or burns, and that the warm heat sensation lasted longer.
In Taiwan, HIPER is expected to break the prejudice against existing high-frequency therapy and become the new standard for high-frequency pain therapy devices.